President Trump listens to FDA Commissioner Stephen Hahn speaking at a press briefing on the Covid-19 pandemic with members of the Coronavirus Task Force at the White House in Washington on March 19, 2020. Photo by Yuri Gripas/Abaca/Sipa USA(Sipa via AP Images)

March 20, 2020 06:44 AM EDTUpdated 08:30 AM

Drugmaker rethinks its decision to double price of a generic after Trump calls it a coronavirus lifesaver — reports

Natalie Grover

Reporter

After President Trump on Thursday implied a decades-old malaria drug was sanctioned by the FDA to fight the new coronavirus, reports emerged that late last …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Drugmaker rethinks its decision to double price of a generic after Trump calls it a coronavirus lifesaver — reports

Natalie Grover

Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Drug­mak­er re­thinks its de­ci­sion to dou­ble price of a gener­ic af­ter Trump calls it a coro­n­avirus life­saver — re­ports

Natalie Grover

Reporter

Sign up to read this article for free.

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Drugmaker rethinks its decision to double price of a generic after Trump calls it a coronavirus lifesaver — reports

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?